Newsfeeds - Spark Newswire

2 minute read

FDA And Health Canada Clear IND For FSD Pharma To Proceed With Phase 2 Trial Of FSD201 For Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome

September 6, 8:32 AM

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to

CSE:HUGE

1 minute read

FSD Pharma Closes CA$16.4M Sale Of Ontario Cannabis Processing Facility, Here’s What’s Next

By Jelena Martinovic

May 10, 10:19 AM

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) has closed the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CA$16.4 million ($12.65 million) in cash.

CSE:HUGE

2 minute read

FSD Pharma Signs Agreement With Covar Pharmaceuticals To Support Development Of Lucid-PSYCH

By Bill Haddad

October 19, 8:45 AM

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced

CSE:HUGE

6 minute read

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold

By Natan Ponieman

August 30, 11:21 AM

Contents

AWKNF

2 minute read

Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals

By Natan Ponieman

August 25, 5:10 PM

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE), a life sciences holding company looking at cannabinoid and psychedelic-based medicines, announced it is entering a definitive agreement to acquire Lucid Psycheceuticals Inc.

CSE:HUGE

4 minute read

FSD Pharma To Acquire Lucid Psycheceuticals; Transaction Will Involve Issuance Of ~4.5M Class B Share sOf FSD With Deemed Aggregate Purchase Price Of ~$9M

By Bill Haddad

August 25, 9:02 AM

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal

CSE:HUGE

2 minute read

FDA
News

FSD Pharma Inc. Announces Termination Of FSD-201 Phase 2 Clinical Trial

By Benzinga Newsdesk

August 24, 4:02 PM

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) (the "Company" or "FSD") announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide

CSE:HUGE